Julia Bonavitacola

Altering gut motility, fueling inflammation, and disturbing microbes are some of the ways stress and anxiety can disrupt gut health.

Kathy Oubre, MS, discusses opportunities for community cancer centers to expand service lines without sacrificing care quality.

Evinacumab-dgnb approval expands treatment options for children with homozygous familial hypercholesterolemia (HoFH).

The approval of paltusotine (Palsonify; Crinetics) marks the first for a once-daily, oral therapy to treat acromegaly.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies.

Panelists discussed the ingredients of successful handoffs at the time of cancer diagnosis and ways to collaborate as screening capabilities evolve.

Consolidation in oncology is creating access and cost challenges, whereas advocacy helps improve patient care and treatment availability, according to Sucharu "Chris" Prakash, MD.

Jeremiah J. Duby, PharmD, BCPS, BCCCP, describes supporting pharmacy residents at the University of California (UC), Davis, in his role as a research advisor.

Children who had chronic, early-onset, nonanterior uveitis were at an increased risk of developing other complications surrounding the eye.

Adherence can lead to better outcomes, higher starts for Medicare Advantage plans, and stronger financial performance.

From proactive recruitment to academic-community partnerships, Hope Krebill highlights ways to improve clinical trial participation.

Any potential reduction in access to pre-exposure prophylaxis (PrEP) would increase both cost and the number of diagnoses of HIV.

The availability of retail pharmacies throughout the country have changed the health system in terms of accessibility and treatment, explains Mark Riggle, PharmD.

Funding cuts to childhood cancer research have put the subspecialty in a precarious position during Childhood Cancer Awareness Month.

The ease of acquiring prior authorizations for a new formulary drug plays a part in evaluating oncology drugs that are new to the market.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.

Despite higher burden of metabolic issues, individuals with HIV were not more metabolically ill.

Accessibility to gender-affirming surgery needs to be improved for transgender, nonbinary, and gender-diverse individuals.

Increased use of neoadjuvant chemotherapy (NACT) with interval debulking surgery has changed surgical practice patterns, improving complete resection rates and reducing postoperative complications.

The governors California, Oregon, Washington, and Hawaii came together to announce their winter virus recommendations.

Net health care costs would also increase by billions of dollars should pre-exposure prophylaxis become less accessible.

New demands to follow the most favored nation executive order could lead to some compliance but it is unknown just how effective they will be across all health care.

Although children living with myopia taking atropine did experience an increased incidence of cataracts, glaucoma, or maculopathy, it is unclear if this risk was confounded by myopia severity.

A reduction in HIV incidence is possible with more structured choices for pre-exposure and postexposure prophylaxis being offered to patients at risk of HIV.

A new study highlights the epidemiological, humanistic, and economic impact of pediatric psoriasis, with findings showing greater challenges in moderate to severe cases.

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.

Experts in cardiometabolic conditions gathered in Aurora, Colorado, on August 19, 2025, to discuss the methods available to prevent cardiovascular events.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.